ArticleEuropean radiology2026
Prevalence and prognosis of non-dilated left ventricular cardiomyopathy in patients referred for cardiac magnetic resonance.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Dilated Left Ventricular Cardiomyopathy: Exploring the Spectrum from Phenotype to Disease Entity.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe European Society of Cardiology recently identified non-dilated left ventricular cardiomyopathy (NDLVC) as a distinct clinical entity. This study aimed to determine the prevalence and prognosis of NDLVC in a specific cohort. MATERIALS AND
methodsThis retrospective cohort analysis included patients referred for routine cardiac magnetic resonance (CMR) and who underwent stress myocardial perfusion or viability assessment from September 2017 to July 2020. Patients with coronary artery disease (CAD) from history or CMR imaging were excluded. Participants were categorized into dilated cardiomyopathy (DCM), NDLVC, and control groups. NDLVC was defined as the presence of non-ischemic LGE or isolated global left ventricular hypokinesia without left ventricular dilatation. The primary endpoints were all-cause mortality or heart failure events.
resultsAmong 4377 CMR patients, 2278 patients remain after the exclusion. Mean age was 66.3 ± 13.2 years, and 60.4% were females. Upon categorization, there were 1996 controls (87.6%), 172 DCM patients (7.6%), and 110 NDLVC patients (4.8%). Among the NDLVC patients, 64 patients (58.2%) had non-ischemic LGE, which included mid-wall, subepicardial, patchy and right ventricular insertion types. Over a median follow-up of 37.5 months, DCM patients exhibited higher rates of composite outcomes than NDLVC and control patients. Likewise, NDLVC patients also had significantly greater rates of composite outcomes and heart failure events than the controls.
conclusionNDLVC had a prevalence of 2.5% among routine stress or viability CMR cases and had a significantly higher rate of clinical outcomes than the controls but lower than DCM patients. These findings underscore the distinct clinical significance of NDLVC. KEY POINTS: Question What is the prevalence and clinical prognosis of non-dilated left ventricular cardiomyopathy (NDLVC) in patients undergoing routine stress or viability cardiac MRI? Findings NDLVC was present in 2.5% of patients undergoing routine stress or viability cardiac MRI and was associated with worse clinical outcomes than controls, but more favorable than dilated cardiomyopathy. Clinical relevance Identifying NDLVC on routine cardiac magnetic resonance (CMR) provides prognostic value, helping to recognize patients at increased risk of heart failure events despite preserved left ventricular size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.